WO2006064449A1 - Detoxifying and immunity-booster composition - Google Patents
Detoxifying and immunity-booster composition Download PDFInfo
- Publication number
- WO2006064449A1 WO2006064449A1 PCT/IB2005/054183 IB2005054183W WO2006064449A1 WO 2006064449 A1 WO2006064449 A1 WO 2006064449A1 IB 2005054183 W IB2005054183 W IB 2005054183W WO 2006064449 A1 WO2006064449 A1 WO 2006064449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment composition
- approximately
- composition
- immunity
- base
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000002509 fulvic acid Substances 0.000 claims abstract description 22
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims abstract description 20
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940095100 fulvic acid Drugs 0.000 claims abstract description 20
- 230000036039 immunity Effects 0.000 claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 241000251468 Actinopterygii Species 0.000 claims abstract description 5
- 239000000839 emulsion Substances 0.000 claims abstract description 5
- 239000004021 humic acid Substances 0.000 claims abstract description 5
- 235000013379 molasses Nutrition 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 10
- 241000193417 Brevibacillus laterosporus Species 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 229960002181 saccharomyces boulardii Drugs 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000027499 body ache Diseases 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to a treatment composition for use in treating human subjects to enhance their general immunity.
- the invention also extends to a method of producing the treatment composition.
- a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the treatment composition comprising a base composition of microbes, and fulvic acid.
- the treatment composition may comprise approximately 50% by volume of the base composition added to approximately 50% by volume of fulvic acid.
- the base composition also may include humic acids, amino acids, molasses, water and/or fish emulsion or extract.
- the base composition may have a pH of between 2.8 and 3.6, and preferably a pH of 3.2.
- the microbes of the base composition may be Bacillus Laterosporus, although the applicant anticipates that other microbes could also be used, including Lactobacillus and Saccharomyces boulardii.
- the fulvic acid may have a concentration of approximately 9%.
- the composition also may include one or more selected vitamins.
- the vitamins may constitute approximately 1% of the composition.
- a method of producing a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects including the steps of multiplying a base culture of a microbe, for example Bacillus Laterosporus, Lactobacillus or Saccharomyces boulardii, in a suitable growth medium; preparing an approximately 9% concentration of fulvic acid; preparing a base composition including amino acids, fulvic acids, humic acids, molasses, water and/or fish emulsion or extract; introducing the base culture into the base composition and allowing the base culture further to multiply until it reaches a concentration of approximately 10 million and above organisms per millilitre; and introducing approximately 50% by volume of the base composition to approximately 50% by volume of the fulvic acid.
- the method may include the steps of maintaining the treatment composition at approximately 23 0 C and in the absence of UV light. It may include the further step of stirring the treatment composition at least once a day.
- the invention extends to a treatment composition comprising a base composition of microbes, and fulvic acid for use in enhancing immunity in human subjects.
- the invention also includes the use of a base composition of microbes, and fulvic acid in the preparation of a detoxifying and immunity-booster treatment composition for use in enhancing immunity in human subjects.
- the base composition had a pH of between 3.8 and 4.
- the base composition was left, for a few days until the Bacillus Laterosporus had multiplied to a concentration of approximately 10 million organisms per millilitre.
- the applicant then prepared fulvic acid at a concentration of approximately 9% and added approximately 50% by volume of the base composition to approximately 50% by volume of the fulvic acid.
- the treatment composition so obtained had a pH of approximately 3.2.
- the treatment composition was subsequently used in experimental trials during which it was given to a number of human patients suffering from one or more of the following conditions, namely HIV and Aids, tuberculosis, immunity deficiencies, and poor digestion.
- the treatment composition according to the invention was given to five patients who were already in an advanced stage of infection. Some of these patients suffered from chronic illness and were no longer able to function properly. After receiving the treatment composition for a period of 6 weeks, conditions of these patients had improved sufficiently enough to enable them to function normally. Some of the chronically ill patients had improved so dramatically that they were able to return to work on a fulltime basis.
- TB tuberculosis
- the treatment composition was also given to five body builders on a daily basis. It was found that the treatment composition had a similar effect on muscle building than anabolic steroids, without the presence of unwanted side effects normally experienced with the latter. It was suggested that the treatment composition could be used as an alternative to plant protein supplements that are often consumed by body builders.
- Digestive track dysfunction The treatment composition was also given to patients who were suffering from stomach ailments, and particularly from diarrhoea. These patients recovered within 30 minutes of taking the treatment composition.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the treatment composition comprising a base composition of microbes, and fulvic acid. In particular, the treatment composition may comprise approximately 50% by volume of the base composition added to approximately 50% by volume of fulvic acid. The base composition also may include humic acids, molasses, water and/or fish emulsion or extract. The fulvic acid may have a concentration of approximately 9%.
Description
DETOXIFYING AND IMMUNITY-BOOSTER COMPOSITION
TECHNICAL FIELD
This invention relates to a treatment composition for use in treating human subjects to enhance their general immunity. The invention also extends to a method of producing the treatment composition.
DISCLOSURE OF THE INVENTION
According to a first aspect of the invention there is provided a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the treatment composition comprising a base composition of microbes, and fulvic acid.
The treatment composition may comprise approximately 50% by volume of the base composition added to approximately 50% by volume of fulvic acid.
The base composition also may include humic acids, amino acids, molasses, water and/or fish emulsion or extract.
The base composition may have a pH of between 2.8 and 3.6, and preferably a pH of 3.2.
The microbes of the base composition may be Bacillus Laterosporus, although the applicant anticipates that other microbes could also be used, including Lactobacillus and Saccharomyces boulardii.
The fulvic acid may have a concentration of approximately 9%.
The composition also may include one or more selected vitamins. The vitamins may constitute approximately 1% of the composition.
According to another aspect of the invention there is provided a method of producing a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the method including the steps of multiplying a base culture of a microbe, for example Bacillus Laterosporus, Lactobacillus or Saccharomyces boulardii, in a suitable growth medium; preparing an approximately 9% concentration of fulvic acid; preparing a base composition including amino acids, fulvic acids, humic acids, molasses, water and/or fish emulsion or extract; introducing the base culture into the base composition and allowing the base culture further to multiply until it reaches a concentration of approximately 10 million and above organisms per millilitre; and introducing approximately 50% by volume of the base composition to approximately 50% by volume of the fulvic acid.
The method may include the steps of maintaining the treatment composition at approximately 230C and in the absence of UV light. It may include the further step of stirring the treatment composition at least once a day.
The invention extends to a treatment composition comprising a base composition of microbes, and fulvic acid for use in enhancing immunity in human subjects.
The invention also includes the use of a base composition of microbes, and fulvic acid in the preparation of a detoxifying and immunity-booster treatment composition for use in enhancing immunity in human subjects.
SPECIFIC EMBODIMENT OF THE INVENTION
Without limiting the scope thereof, the invention will now further be described by way of examples only.
The applicant prepared 1000 litres of a base composition as follows:
The base composition had a pH of between 3.8 and 4.
The base composition was left, for a few days until the Bacillus Laterosporus had multiplied to a concentration of approximately 10 million organisms per millilitre. The applicant then prepared fulvic acid at a concentration of approximately 9% and added approximately 50% by volume of the base composition to approximately 50% by volume of the fulvic acid. The treatment composition so obtained had a pH of approximately 3.2.
The treatment composition was subsequently used in experimental trials during which it was given to a number of human patients suffering from one or more of the following conditions, namely HIV and Aids, tuberculosis, immunity deficiencies, and poor digestion.
In cases of severe lack of immunity, patients received 10 ml of the treatment composition with 250 ml of water after breakfast. In less severe cases, patients received a dosage of 5 ml of the treatment composition with 250 ml water after breakfast. It was found that if the treatment composition were taken late in the afternoon, some patients encountered difficulties in falling asleep. The applicant believes that this results from an increased metabolism caused by the treatment composition. After 2 weeks' treatment with the treatment composition, patients were subjected to detoxifying exercises to effect drainage of the limbic system. In some cases, this resulted in short-term body aches resulting from the detoxifying process.
HIV and Aids patients
The treatment composition according to the invention was given to five patients who were already in an advanced stage of infection. Some of these patients suffered from chronic illness and were no longer able to function properly. After receiving the treatment composition for a period of 6 weeks, conditions of these patients had improved sufficiently enough to enable them to function normally. Some of the chronically ill patients had improved so dramatically that they were able to return to work on a fulltime basis.
Patients suffering from tuberculosis ("TB") The treatment composition was given to three patients that had been suffering from TB in excess of 2 years. After treatment with the treatment composition for a period of 2 months, the patients had recovered completely from TB.
Patients suffering from immunity deficiencies Twenty patients that were all suffering from chronic immunity deficiencies were treated with the treatment composition according to the invention by daily dosing with the composition. Initially, during the detoxifying phase, the majority of patients complained of various body aches. However, after only one month, the patients' conditions had improved remarkably and the feedback was very positive. Previously chronic infections had been cured and it was no longer necessary to take pro-biotic supplements to stabilise the immune system.
After two months' treatment most female patients' hormonal functions and muscle tone had improved, and menstrual cycles had normalised.
Body builders
The treatment composition was also given to five body builders on a daily basis. It was found that the treatment composition had a similar effect on muscle building than anabolic steroids, without the presence of unwanted side effects normally experienced with the latter. It was
suggested that the treatment composition could be used as an alternative to plant protein supplements that are often consumed by body builders.
Digestive track dysfunction The treatment composition was also given to patients who were suffering from stomach ailments, and particularly from diarrhoea. These patients recovered within 30 minutes of taking the treatment composition.
It will be appreciated that many variations in detail are possible without departing from the spirit or scope of the invention as defined in the claims.
Claims
1. A detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the treatment composition comprising a base composition of microbes, and fulvic acid.
2. The treatment composition according to claim 1 comprising approximately 50% by volume of the base composition added to approximately 50% by volume of fulvic acid.
3. The treatment composition according to claim 1 characterised therein that the base composition also includes humic acids, amino acids, molasses, water and/or fish emulsion or extract
4. The treatment composition according to claim 1 characterised therein that the base composition has a pH of between 2.8 and 3.6, and preferably a pH of 3.2.
5. The treatment composition according to claim 1 characterised therein that the microbes of the base composition may be selected from a group including Bacillus Laterosporus, Lactobacillus or Saccharomyces boulardii.
6. The treatment composition according to claim 1 characterised therein that the fulvic acid has a concentration of approximately 9%.
7. The treatment composition according to claim 1 characterised therein that it also includes one or more selected vitamins, more particularly the vitamins may constitute approximately 1% of the composition.
8. A method of producing a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the method including the steps of multiplying a base culture of a microbe, for example Bacillus Laterosporus, Lactobacillus or Saccharomyces boulardii, in a suitable growth medium; preparing an approximately 9% concentration of fulvic acid; preparing a base composition including amino acids, fulvic acids, humic acids, molasses, water and/or fish emulsion or extract; introducing the base culture into the base composition and allowing the base culture further to multiply until it reaches a concentration of approximately 10 million and above organisms per millilitre; and introducing approximately 50% by volume of the base composition to approximately 50% by volume of the fulvic acid.
9. The method according to claim 8 characterised therein that it includes the steps of maintaining the treatment composition at approximately 230C and in the absence of UV light.
10. The method according to claim 8 characterised therein that it includes the further step of stirring the treatment composition at least once a day.
11. A treatment composition comprising a base composition of microbes, and fulvic acid for use in enhancing immunity in human subjects.
12. The use of a base composition of microbes, and fulvic acid in the preparation of a detoxifying and immunity-booster treatment composition for use in enhancing immunity in human subjects.
13. A detoxifying and immunity-booster treatment composition according to claims 1 and 11 substantially as herein described and exemplified with reference to the accompanying examples.
14. A method of producing a detoxifying and immunity-booster treatment composition according to claim 8 substantially as herein described and exemplified with reference to the accompanying examples.
15. The use of a base composition of microbes, and fulvic acid according to claim 12 substantially as herein described and exemplified with reference to the accompanying examples.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2004/10130 | 2004-12-15 | ||
| ZA200410130 | 2004-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006064449A1 true WO2006064449A1 (en) | 2006-06-22 |
Family
ID=36010940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2005/054183 WO2006064449A1 (en) | 2004-12-15 | 2005-12-12 | Detoxifying and immunity-booster composition |
Country Status (2)
| Country | Link |
|---|---|
| WO (1) | WO2006064449A1 (en) |
| ZA (1) | ZA200705844B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2753609C1 (en) * | 2020-10-16 | 2021-08-18 | Николай Иванович Милов | Antiviral humic agent |
| WO2022041352A1 (en) * | 2020-08-26 | 2022-03-03 | 河北科星药业有限公司 | Feed additive for preventing diarrhea and improving immunity, and preparation method therefor and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2674755A1 (en) * | 1991-04-05 | 1992-10-09 | Thorel Jean Noel | Novel immunostimulatory medicinal compositions |
| WO2000019999A1 (en) * | 1998-10-08 | 2000-04-13 | Enerkom (Proprietary) Limited | Fulvic acid and its use in the treatment of various conditions |
| US20040029127A1 (en) * | 2000-05-25 | 2004-02-12 | Eric Postaire | Use of lactobacillus case in immunostimulatory peptides |
| WO2004034808A1 (en) * | 2002-10-18 | 2004-04-29 | Biogaia Ab | Method of improving immune function in mammals using lactobacillus reuteri strains |
| WO2005036969A1 (en) * | 2003-10-15 | 2005-04-28 | Van Der Westhuizen Cornelis Fl | Composition for treating crops and plants against nematodes |
-
2005
- 2005-12-12 WO PCT/IB2005/054183 patent/WO2006064449A1/en not_active Application Discontinuation
- 2005-12-12 ZA ZA200705844A patent/ZA200705844B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2674755A1 (en) * | 1991-04-05 | 1992-10-09 | Thorel Jean Noel | Novel immunostimulatory medicinal compositions |
| WO2000019999A1 (en) * | 1998-10-08 | 2000-04-13 | Enerkom (Proprietary) Limited | Fulvic acid and its use in the treatment of various conditions |
| US20040029127A1 (en) * | 2000-05-25 | 2004-02-12 | Eric Postaire | Use of lactobacillus case in immunostimulatory peptides |
| WO2004034808A1 (en) * | 2002-10-18 | 2004-04-29 | Biogaia Ab | Method of improving immune function in mammals using lactobacillus reuteri strains |
| WO2005036969A1 (en) * | 2003-10-15 | 2005-04-28 | Van Der Westhuizen Cornelis Fl | Composition for treating crops and plants against nematodes |
Non-Patent Citations (1)
| Title |
|---|
| MEYDANI S N ET AL: "IMMUNOLOGIC EFFECTS OF YOGURT", AMERICAN JOURNAL OF CLINICAL NUTRITION, BETHESDA,MD, US, vol. 71, no. 4, 2000, pages 861 - 872, XP000952410, ISSN: 0002-9165 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022041352A1 (en) * | 2020-08-26 | 2022-03-03 | 河北科星药业有限公司 | Feed additive for preventing diarrhea and improving immunity, and preparation method therefor and application thereof |
| RU2753609C1 (en) * | 2020-10-16 | 2021-08-18 | Николай Иванович Милов | Antiviral humic agent |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200705844B (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agrawal et al. | Hypoglycemic activity of camel milk in streptozotocin induced diabetic rats | |
| US6759061B2 (en) | Liver function improvement formulation | |
| CN105555150A (en) | Composition for enhancing immunity | |
| RU2309751C1 (en) | Method for treating the disorders of mineral metabolism at arthritis, or osteochondrosis, or rickets, or arthrosis, or osteoporosis | |
| CN111419882A (en) | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof | |
| WO2006064449A1 (en) | Detoxifying and immunity-booster composition | |
| McClain et al. | Severe zinc deficiency presenting with acrodermatitis during hyperalimentation: diagnosis, pathogenesis, and treatment | |
| CN1436490A (en) | Production process of natural marine organism health food with deep sea clam worm as material | |
| Free et al. | The Use of Ascorbic Acid and Mineral Supplements in the Deroxification of Narcotic Addicts | |
| Alexander et al. | The role of fecal thiamine and cocarboxylase in human nutrition | |
| Fraenkel | Isolation procedures and certain properties of vitamin BT | |
| CN1252231A (en) | Hemoglobin food series and its production process | |
| CN102327603B (en) | Preparation method and use method of loach aeromonas sobria vaccine | |
| Hamadeh et al. | Hypercalcemia in a bodybuilder with cosmetic silicone injections | |
| CN101048081A (en) | Nutritional and/or pharmaceutical preparations for the prevention and treatment of disorders of absorption of trace elements from the digestive tract | |
| CN1042797C (en) | Antibacterial antiviral oral liquid | |
| US20230285308A1 (en) | Capsule to support the body's defense against microplastics | |
| CN109432304A (en) | A kind of application of composition containing dendrobium candidum in medicine preparation | |
| CN114767716B (en) | A kind of kefir whey and tea polyphenols composition and its preparation method and application | |
| RU2746642C1 (en) | Method for complex sequential use of pathogenetic agents in treatment in children with tuberculosis infection | |
| Zemskov et al. | Principles for the Purpose of Immunotherapy | |
| Elam | Effect of Biogen and Bio-Mos on growth performance, production and some biochemical changes in Oreochromis niloticus and Mugil cephalus. The First Sci | |
| JP2826007B2 (en) | Race performance running performance improving feed or feed additive | |
| RU2464034C2 (en) | Method of treating tuberculosis complicated by intolerance to chemotherapy | |
| US9056124B2 (en) | Method for the treatment of tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05825687 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05825687 Country of ref document: EP Kind code of ref document: A1 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 5825687 Country of ref document: EP |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, EPO FORM 1205A DATED 27.12.07 |